{"filing":{"accession_number":"0001171843-26-005324","cik":"0001627281","ticker":"CLLS","company_name":"Cellectis S.A.","form":"6-K","filing_date":"2026-08-06","report_date":"2026-08-06","primary_document":"f6k_080626.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1627281/000117184326005324/f6k_080626.htm"},"events":[{"id":24608,"run_id":22309,"accession_number":"0001171843-26-005324","anchor_item_number":"EX-99.1","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"This is a press release disclosing Cellectis' financial results for the second quarter 2026 (six-month period ended June 30, 2026), including consolidated statements of financial position, operations, and per-share metrics. The document presents both interim financial statements and operational updates on clinical trials (lasme-cel, eti-cel), regulatory milestones (FDA RMAT designation), and cash position ($169 million). As a clinical-stage biotech company, these results and regulatory developments are material to investors assessing the registrant's progress and financial runway.","company_name":"Cellectis S.A.","ticker":"CLLS","filing_date":"2026-08-06","form":"6-K","submitted_at":null,"items":[{"id":25225,"accession_number":"0001171843-26-005324","item_number":"EX-99.1","item_title":"exh_991.htm","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This is a press release disclosing Cellectis' financial results for the second quarter 2026 (six-month period ended June 30, 2026), including consolidated statements of financial position, operations, and per-share metrics. The document presents both interim financial statements and operational updates on clinical trials (lasme-cel, eti-cel), regulatory milestones (FDA RMAT designation), and cash position ($169 million). As a clinical-stage biotech company, these results and regulatory developments are material to investors assessing the registrant's progress and financial runway.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-08-07T00:19:43.537693+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":25225,"accession_number":"0001171843-26-005324","item_number":"EX-99.1","item_title":"exh_991.htm","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This is a press release disclosing Cellectis' financial results for the second quarter 2026 (six-month period ended June 30, 2026), including consolidated statements of financial position, operations, and per-share metrics. The document presents both interim financial statements and operational updates on clinical trials (lasme-cel, eti-cel), regulatory milestones (FDA RMAT designation), and cash position ($169 million). As a clinical-stage biotech company, these results and regulatory developments are material to investors assessing the registrant's progress and financial runway.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-08-07T00:19:43.537693+00:00","company_name":"Cellectis S.A.","ticker":"CLLS","filing_date":"2026-08-06"}]}